The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing ...

Începând cu 15 septembrie, medicamentul interferon alfa-2b va fi disponibil la Institutul Oncologic pentru pacienții care au ...

Pacienții care au nevoie de interferon alfa-2b își vor putea continua tratamentul. Ministerul Sănătății anunță că medicamentul va fi din nou disponibil la Institutul Oncologic, începând cu 15 septembr ...

Ropeginterferon alfa-2b-njft is expected to be available immediately.

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver ...

Medicamentul Interferon alfa-2b va fi disponibil, începând cu 15 septembrie, la Institutul Oncologic pentru pacienții care au ...

Arbutus Biopharma (ABUS) was able to report positive data from its phase 2a IM-PROVE I trial, which used its drug Imdusiran [AB-729] together with short courses of pegylated interferon alfa-2a to ...

Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...

PharmaEssentia a reçu l'approbation de la Food and Drug Administration pour le ropeginterferon alfa-2b-njft chez les adultes atteints de thrombocytémie essentielle . Il s'agit du premier ...

Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), such as essential ...

Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases September 1, 2026 8:30 AM ...